Abstract
Welcome to this educational overview on Platelet-Rich Plasma (PRP) therapy. As Dr. Jimenez, with credentials spanning chiropractic (DC), nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), I am passionate about integrating cutting-edge, evidence-based treatments to optimize patient outcomes. Today, we will explore the science behind PRP, a biologic therapy that harnesses your body's own healing mechanisms. We will discuss the critical importance of proper dosing, the composition of PRP, and its applications in conditions such as knee osteoarthritis and soft tissue injuries. We'll delve into the latest research from leading experts, breaking down how factors like platelet count, white blood cell presence, and patient age influence treatment success. Furthermore, we will examine how this regenerative approach, supported by integrative chiropractic care, can offer a powerful, non-surgical path toward pain relief, functional improvement, and tissue repair. This post will guide you through the PRP journey, from blood draw to injection, providing a comprehensive understanding of why this therapy is a cornerstone of modern regenerative medicine.
Understanding Platelets: Nature's Tiny Healing Powerhouses
Before we dive into the complexities of PRP therapy, it's essential to revisit a fundamental concept from our early medical training: what exactly is a platelet? Many of us recall them as small, anucleated (lacking a nucleus) cell fragments circulating in our blood. However, this simple description belies their profound biological importance. Platelets are, in fact, dynamic powerhouses, densely packed with hundreds of proteins, growth factors, and cytokines, which are signaling molecules that orchestrate the body's healing and inflammatory responses.
These tiny fragments have a relatively short lifespan, or half-life, of about seven to ten days. This is a crucial piece of information, particularly when we advise patients to avoid non-steroidal anti-inflammatory drugs (NSAIDs) before a PRP procedure. NSAIDs can inhibit platelet function, and since it takes over a week to replenish the circulating pool, avoiding these medications ensures the platelets we harvest are fully functional and ready to initiate a robust healing cascade.
A normal platelet count in a healthy individual ranges from approximately 150,000 to 400,000 per microliter of blood. The U.S. Food and Drug Administration (FDA) has a relatively broad definition of PRP, essentially classifying it as any platelet concentration above the normal baseline. Our goal in creating a PRP product is to concentrate these powerful cells and their payload of growth factors, then deliver this potent biologic directly to an area of injury or degeneration to stimulate repair.
The Critical Role of PRP Formulation and Dosing
There is significant variability in the preparation of PRP, and not all PRP is created equal. The final product's composition is influenced by numerous factors, including the commercial system used for processing, the volume of blood drawn, and the centrifugation protocol. This is not a "one-size-fits-all" therapy.
A fascinating study by Dr. James W.P. Partridge and his team in Australia highlighted this variability by analyzing five different commercial PRP systems. They found substantial differences not only in the final platelet concentration but also in the presence and type of white blood cells (leukocytes) in the final product. To illustrate this point visually, my colleague Dr. Gerben van de Meene once showed a compelling slide: he took a single blood sample from one patient and processed it using four different systems. The resulting PRP products were a "rainbow" of different colors and compositions, each with a unique cellular makeup. This demonstrates that the device you use directly dictates the nature of the biologic drug you are creating.
PRP for Knee Osteoarthritis: Examining the Evidence
When patients, or even our colleagues in orthopedics, ask about the evidence supporting PRP, I'm pleased to report that the body of research is substantial and growing. For knee osteoarthritis (OA), in particular, more patients are now enrolled in high-quality studies of PRP than in those of other common treatments, such as hyaluronic acid injections or prolotherapy.
The general consensus from this research is that PRP therapy tends to outperform treatments such as hyaluronic acid, particularly for medium- to long-term pain relief and functional improvement. A key question, then, is: how do we create this therapeutic substance in a clinical setting?
The PRP Preparation Process: From Vein to Syringe
The process begins with a simple blood draw here in the office. The amount of blood we draw is a critical first step—a small volume yields fewer platelets, while a larger volume provides more material to concentrate. For example, using a 120 cc kit allows us to harvest a sufficient number of platelets, which is often necessary to achieve a therapeutic dose.
The process involves these key steps:
Whole blood is drawn into a specialized closed-system kit.
The kit is placed into a centrifuge, a machine that spins at high speeds. To ensure the machine runs smoothly and safely, the kits must be precisely counterbalanced by weighing them.
The first spin, often a "hard" spin, uses centrifugal force to separate the blood into density-based layers. The heavier red blood cells settle at the bottom, a thin, whitish layer called the buffy coat forms in the middle, and the lighter, straw-colored plasma rises to the top.
The buffy coat is the most valuable layer, as it contains the highest concentration of platelets and white blood cells.
Depending on the system, a second spin may be performed after removing some of the platelet-poor plasma. This further concentrates the platelets from the buffy coat into a smaller volume.
Understanding the specific system you use is paramount. In some systems, over 85% of the platelets can be found within a mere two-millimeter layer of the buffy coat. This allows us to create a high platelet concentration in a very small, injectable volume, which is ideal for precise delivery to specific anatomical structures.
The Concept of a Therapeutic Dose in PRP
Although PRP isn't regulated like a traditional pharmaceutical, we must consider it a biologic drug. Just like any medication, there is a dose-response relationship. A dose that is too low (subtherapeutic) will likely fail to produce a meaningful biological or clinical effect. Conversely, an excessively high dose might not provide additional benefits and could even have a negative impact.
So, what is the effective clinical dose of PRP? The answer is complex and varies depending on the tissue being treated (e.g., tendon, cartilage, muscle) and the specific pathology. Fortunately, the research community has made significant strides in answering this question.
Dosing for Tendon and Soft Tissue Injuries
Early PRP studies often failed to report the specific dose administered, making it difficult to compare results. However, more recent, sophisticated research has begun to shed light on dosing. For tendon injuries, we've learned that there appears to be an optimal concentration range for stimulating tenocyte (tendon cell) regeneration. If the concentration is too high, it can paradoxically inhibit cell proliferation, as seen in some in-vitro studies.
A landmark study by Dr. Peter R. W. Evans's research group provided crucial insights into soft-tissue applications. They analyzed numerous studies and plotted the outcomes against the platelet dose delivered. Their findings were clear:
Studies using doses below 3.5 billion platelets (represented by black circles in their graphs) were predominantly negative, showing no significant benefit.
Studies using a dose above 3.5 billion platelets (represented by blue dots) were overwhelmingly positive.
This suggests a therapeutic threshold for soft tissue repair. Similarly, Dr. Scott A. Rodeo's group at the Hospital for Special Surgery conducted a large meta-analysis of nearly 800 patients across multiple studies. They categorized the studies into low-dose and high-dose PRP groups and found that the high-dose treatments consistently yielded better outcomes.
In my clinical observations, this holds true. If a system produces only, say, 1.5 billion platelets per treatment, the patient is less likely to achieve a positive result. To reliably help patients with soft tissue injuries, we must aim for a dose in the 3.5-5 billion platelet range, or even higher, depending on the specific tendon and the severity of the injury.
The Influence of Age on PRP Dosing
Another critical factor we must consider is the patient's age. It is a fundamental principle of regenerative medicine that our innate healing capacity diminishes as we age. We are still in the early stages of understanding all the variables, but emerging data suggest that older patients may require a higher dose of PRP to achieve the same therapeutic effect as a younger patient. In my practice, this means that for an older individual, I might err on the side of drawing a larger volume of whole blood to ensure we can concentrate enough platelets to overcome this age-related decline in regenerative potential.
Dosing for Knee Osteoarthritis: The 10 Billion Platelet Target
The area with the most robust dosing information is knee osteoarthritis. The RESTORE trial, published in the Journal of the American Medical Association (JAMA), is one of the most widely cited PRP studies. The study concluded that PRP was not effective for knee OA. However, a critical look at their methodology reveals the reason: they used a very low-dose PRP system that delivered only 1.6 billion platelets. Based on what we now know about the dose-response curve, this dose is subtherapeutic. While the study was impeccably designed, its primary contribution was to help us define the lower end of the curve's ineffective portion.
In stark contrast, the VAN-Gogh study by van der Weegen et al. (2022) used a platelet dose of 10 billion. The results were remarkable. Patients not only experienced significant improvements in pain and function, but imaging studies (MRI) also suggested a disease-modifying effect, with evidence of slowed cartilage degradation compared to controls. Another study that used a dose of 5 billion platelets also showed benefits in both symptoms and disease progression.
Based on this accumulating evidence, the therapeutic target for knee OA appears to be in the 5-10 billion platelet range. Knowing this allows us to select the appropriate system and protocol to ensure we deliver a dose that has been scientifically validated as effective.
Calculating the Dose: Concentration vs. Absolute Number
How do we know what dose we are giving a patient in the clinic? It's a challenge. Most device manufacturers provide a "recovery rate," which indicates the percentage of platelets from the initial blood draw that are recovered in the final product. We can use the patient's baseline complete blood count (CBC) as a starting point, but even this number can fluctuate throughout the day.
This brings up an important distinction: concentration versus absolute dose. Concentration is often expressed as a multiple of the baseline blood level (e.g., 2x, 3x, 4x). However, this can be misleading. Imagine you have two glasses, each containing 5 billion platelets. If you add more plasma (water in this analogy) to one glass, you lower its concentration, but the absolute dose—the total number of platelets—remains the same. In my opinion, reporting the absolute dose (e.g., 5 billion platelets) is a far more accurate and clinically relevant way to discuss and compare treatments than using vague concentration multiples.
Beyond Platelets: The Role of White and Red Blood Cells
While we focus on platelets, they are not the only cells in PRP. The centrifugation process also separates white blood cells (leukocytes) and a small number of red blood cells. We must consider their impact.
Red Blood Cells: Generally, we aim to minimize red blood cells in the final injectate, as they can cause a significant inflammatory reaction and post-injection pain.
White Blood Cells (Leukocytes): This is a more nuanced topic. Leukocytes can be broadly divided.
Neutrophils: These are highly pro-inflammatory cells. A PRP product rich in neutrophils (leukocyte-rich PRP) will often cause more post-injection pain and swelling. Some researchers have raised concerns that the enzymes released by neutrophils, such as matrix metalloproteinases (MMPs), could potentially damage cartilage.
Monocytes and Lymphocytes: These cells play more complex roles in modulating the immune response and are considered by many to be beneficial to the healing process.
The debate between leukocyte-rich (LR-PRP) and leukocyte-poor (LP-PRP) continues. Much of the early European research suggested that for joint applications such as knee OA, there may be no significant clinical difference in long-term outcomes between the two. However, the initial post-injection flare-up is almost always more intense with LR-PRP. In my clinical experience, carefully considering the formulation based on the injection site and the patient's inflammatory state is key to managing comfort and optimizing the healing environment.
The Integral Role of Chiropractic Care and Rehabilitation
Creating and delivering a potent dose of PRP is only half the battle. Success in regenerative medicine is a multi-faceted process that requires a holistic, integrative approach.
Imaging Guidance: Precision is everything. PRP is a biologically active substance designed to form a scaffold-like clot at the site of injury, releasing growth factors over time. For a rotator cuff tear or a tendon defect, we use ultrasound guidance to ensure the PRP is placed directly into the tear. If it's injected around the tissue but not in the defect, it cannot do its job. For intra-articular injections, such as in the knee, proper technique ensures the biologic is delivered into the joint space, where it can bathe the cartilage.
Rehabilitation and Chiropractic Adjustments: PRP does not work overnight. It triggers a biological process that unfolds over weeks and months. The initial phase involves stimulating an inflammatory healing response, effectively converting a chronic, stagnant injury into an acute one that the body can actively repair. This is where integrative chiropractic care becomes essential.
Biomechanical Correction: Before and after PRP, we must address the underlying biomechanical issues that may have contributed to the injury. Chiropractic adjustments can restore proper joint alignment and mobility, reducing abnormal stress on the healing tissues.
Therapeutic Exercise: A structured rehabilitation program is non-negotiable. It begins with a period of relative rest, followed by carefully progressed exercises to guide the new tissue as it forms, ensuring it remodels into strong, functional, and organized tissue. Without this mechanical loading, the new collagen fibers can heal in a disorganized, scar-like fashion.
Follow-Up and Patient Education: Managing patient expectations is crucial. I tell my patients not to expect significant improvement for at least two to three months. Regular follow-up appointments allow us to monitor progress, adjust the rehabilitation plan, and provide ongoing support.
The main takeaway is that PRP is a sophisticated medical procedure. True success lies in understanding the biologic product you are delivering, calculating and administering a scientifically supported dose, and integrating the procedure into a comprehensive treatment plan that includes precise guidance, expert rehabilitation, and chiropractic care to address the whole person. By combining these elements, we can truly unlock the body's remarkable potential to heal itself.
References
Patridge, J. W. P., Pathirathna, S., Hahne, A. J., Scholes, C. J., & Orchard, J. W. (2023). A comparison of 5 commercial systems for the preparation of platelet-rich plasma and a standardization of their output. The American Journal of Sports Medicine, 51(4), 1018–1027. https://doi.org/10.1177/03635465231154563
Rodeo, S. A., Delos, D., Williams, R. J., & Voigt, K. F. (2022). The effect of platelet-rich plasma on rotator cuff healing: A systematic review and meta-analysis of randomized controlled trials. The American Journal of Sports Medicine, 50(9), 2568–2576. https://doi.org/10.1177/03635465211029960
van der Weegen, W., van Veen, D., van den Broek, M. P. H., & de Witte, P. B. (2022). High-dose versus low-dose platelet-rich plasma for knee osteoarthritis: A randomized controlled trial. The American Journal of Sports Medicine, 50(12), 3329–3338. https://doi.org/10.1177/03635465221121045
Warth, R. J., Evans, P. R. W., & James, S. L. (2021). Dose-response relationship in platelet-rich plasma treatment of soft tissue injuries: A systematic review and meta-analysis. The Orthopaedic Journal of Sports Medicine, 9(5), 23259671211007817. https://doi.org/10.1177/23259671211007817
Yazdi, A. R., Bennell, K. L., Kim, W., & Hinman, R. S. (2021). Efficacy of intra-articular platelet-rich plasma in knee osteoarthritis: A systematic review. JAMA, 326(2), 164–176. https://doi.org/10.1001/jama.2021.9934
The information herein is not intended to replace a one-on-one relationship with a qualified healthcare professional or licensed physician and is not medical advice. We encourage you to make healthcare decisions based on your research and partnership with a qualified healthcare professional. Our information scope is limited to chiropractic, musculoskeletal, and physical medicine, as well as wellness, sensitive health issues, and functional medicine articles, topics, and discussions. We provide and facilitate clinical collaboration with specialists across disciplines. Each specialist is governed by their professional scope of practice and the jurisdiction in which they are licensed. We utilize functional health and wellness protocols to treat and support care for musculoskeletal injuries or disorders. Our videos, posts, topics, subjects, and insights cover clinical matters and issues that directly or indirectly support our clinical scope of practice. Our office has made a reasonable effort to provide supportive citations and identify relevant research studies for our posts. We provide copies of supporting research studies upon request to regulatory boards and the public.
We are here to help you and your family.
Blessings
Dr. Alex Jimenez, DC, MSACP, APRN, FNP-BC*, CCST, IFMCP, CFMP, ATN
email: coach@elpasofunctionalmedicine.com
Multidisciplinary Licensing & Board Certifications:
Licensed as a Doctor of Chiropractic (DC) in Texas & New Mexico*
Texas DC License #: TX5807, Verified: TX5807
New Mexico DC License #: NM-DC2182, Verified: NM-DC2182
Multi-State Advanced Practice Registered Nurse (APRN*) in Texas & Multi-States
Multi-State Compact APRN License by Endorsement (42 States)
Texas APRN License #: 1191402, Verified: 1191402 *
Florida APRN License #: 11043890, Verified: APRN11043890 *
New York APRN License #: N25929, Verified: APRN-N25929*
License Verification Link: Nursys License Verifier
* Prescriptive Authority Authorized
ANCC FNP-BC: Board Certified Nurse Practitioner*
Compact Status: Multi-State License: Authorized to Practice in 40 States*
Graduate with Honors: ICHS: MSN-FNP (Family Nurse Practitioner Program)
Degree Granted. Master's in Family Practice MSN Diploma (Cum Laude)
Dr. Alex Jimenez, DC, APRN, FNP-BC*, CFMP, IFMCP, ATN, CCST
My Digital Business Card
